Sfoglia per Autore
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives
2015-01-01 Sanlorenzo, Martina; Vujic, Igor; Moy, Adrian; Quaglino, Pietro; Fierro, Maria Teresa; Gammaitoni, Loretta; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma.
2014-01-01 Sangiolo D;Mesiano G;Gammaitoni L;Aglietta M;Grignani G
Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy
2014-01-01 Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Fabrizio CS; Aglietta M; Sangiolo D.
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.
2014-01-01 Sangiolo D; Mesiano G; Gammaitoni L; Leuci V; Todorovic M; Giraudo L; Cammarata C; Dell'aglio C; D'Ambrosio L; Pisacane A; Sarotto I; Miano S; Ferrero I; Carnevale-Schianca F; Pignochino Y; Sassi F; Bertotti A; Piacibello W; Fagioli F; Aglietta M; Grignani G.
Recent advances in the development of breast cancer vaccines.
2014-01-01 Milani A;Sangiolo D;Aglietta M;Valabrega G
Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective.
2014-01-01 Gammaitoni L;Leuci V;Mesiano G;Giraudo L;Todorovic M;Carnevale-Schianca F;Aglietta M;Sangiolo D
Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors.
2014-01-01 Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D.
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
2013-01-01 Milani A;Sangiolo D;Montemurro F;Aglietta M;Valabrega G
Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features.
2013-01-01 Gammaitoni L;Giraudo L;Leuci V;Todorovic M;Mesiano G;Picciotto F;Pisacane A;Zaccagna A;Volpe MG;Gallo S;Caravelli D;Giacone E;Venesio T;Balsamo A;Pignochino Y;Grignani G;Carnevale-Schianca F;Aglietta M;Sangiolo D
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma.
2013-01-01 Pignochino Y;Dell'aglio C;Basirico M;Capozzi F;Soster M;Marchio S;Bruno S;Gammaitoni L;Sangiolo D;Torchiaro E;D'Ambrosio L;Fagioli F;Ferrari S;Alberghini M;Picci P;Aglietta M;Grignani G
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers.
2012-01-01 Todorovic M; Mesiano G; Gammaitoni L; Leuci V; Giraudo Diego L; Cammarata C; Jordaney N; Carnevale-Schianca F; Gallo S; Fagioli F; Piacibello W; Elia AR; Pignochino Y; Dell'aglio C; Grignani G; Cignetti A; Aglietta M; Sangiolo D.
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.
2012-01-01 Mesiano G; Todorovic M; Gammaitoni L; Leuci V; Giraudo Diego L; Carnevale-Schianca F; Fagioli F; Piacibello W; Aglietta M; Sangiolo D.
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways
2012-01-01 Pignochino, Y.; Dell'Aglio, C.; Basirico, M.; Capozzi, F.; Tarraran, L.; Soster, M.; Marchio, S.; Bruno, S.; Gammaitoni, L.; Sangiolo, D.; D'ambrosio, L.; Picci, P.; Aglietta, M.; Grignani, G.
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer
2012-01-01 M. Todorovic; S. Corso; L. Gammaitoni; V. Leuci; G. Mesiano; L. Giraudo Diego; S. Capellero; S. Giordano; M. Aglietta; D. Sangiolo
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?
2011-01-01 Carnevale-Schianca F; Gallo S; Rota-Scalabrini D; Sangiolo D; Fizzotti M; Caravelli D; Capaldi A; Anselmetti G; Palesandro E; D'Ambrosio L; Coha V; Obert R; Aglietta M; Grignani G.
Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks.
2011-01-01 Sangiolo D; Leuci V; Gallo S; Aglietta M; Piacibello W.
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors.
2011-01-01 Leuci V; Mesiano G; Gammaitoni L; Cammarata C; Capellero S; Todorovic M; Jordaney N; Circosta P; Elia A; Lesnikova M; Georges GE; Piacibello W; Fagioli F; Cignetti A; Aglietta M; Sangiolo D
Cytokine induced killer cells as promising immunotherapy for solid tumors
2011-01-01 Sangiolo, Dario
Comparison of post-transplant events and outcomes in patients affected by haematological or solid malignancies undergone to a non-myeloablative allogeneic haematopoietic stem cell transplantation in progressive disease
2010-01-01 Caravelli D; Carnevale-Schianca F; Bruno B; Coha V; Sorasio R; Grignani G; Rota-Scalabrini D; Fizzotti M; Gatti M; Giaccone L; Capaldi A; Cignetti A; Sangiolo D; Boccadoro M; Aglietta M
Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age.
2010-01-01 Sangiolo D;Storb R;Deeg HJ;Flowers ME;Martin PJ;Sandmaier BM;Kiem HP;Nash RA;Doney K;Leisenring WM;Georges GE
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives | 2015 | Sanlorenzo, Martina; Vujic, Igor; Moy, Adrian; Quaglino, Pietro; Fierro, Maria Teresa; Gammaitoni, Loretta; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario | |
| Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. | 2014 | Sangiolo D;Mesiano G;Gammaitoni L;Aglietta M;Grignani G | |
| Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy | 2014 | Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Fabrizio CS; Aglietta M; Sangiolo D. | |
| Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. | 2014 | Sangiolo D; Mesiano G; Gammaitoni L; Leuci V; Todorovic M; Giraudo L; Cammarata C; Dell'aglio C; D'Ambrosio L; Pisacane A; Sarotto I; Miano S; Ferrero I; Carnevale-Schianca F; Pignochino Y; Sassi F; Bertotti A; Piacibello W; Fagioli F; Aglietta M; Grignani G. | |
| Recent advances in the development of breast cancer vaccines. | 2014 | Milani A;Sangiolo D;Aglietta M;Valabrega G | |
| Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. | 2014 | Gammaitoni L;Leuci V;Mesiano G;Giraudo L;Todorovic M;Carnevale-Schianca F;Aglietta M;Sangiolo D | |
| Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. | 2014 | Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D. | |
| Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. | 2013 | Milani A;Sangiolo D;Montemurro F;Aglietta M;Valabrega G | |
| Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. | 2013 | Gammaitoni L;Giraudo L;Leuci V;Todorovic M;Mesiano G;Picciotto F;Pisacane A;Zaccagna A;Volpe MG;Gallo S;Caravelli D;Giacone E;Venesio T;Balsamo A;Pignochino Y;Grignani G;Carnevale-Schianca F;Aglietta M;Sangiolo D | |
| The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma. | 2013 | Pignochino Y;Dell'aglio C;Basirico M;Capozzi F;Soster M;Marchio S;Bruno S;Gammaitoni L;Sangiolo D;Torchiaro E;D'Ambrosio L;Fagioli F;Ferrari S;Alberghini M;Picci P;Aglietta M;Grignani G | |
| Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. | 2012 | Todorovic M; Mesiano G; Gammaitoni L; Leuci V; Giraudo Diego L; Cammarata C; Jordaney N; Carnevale-Schianca F; Gallo S; Fagioli F; Piacibello W; Elia AR; Pignochino Y; Dell'aglio C; Grignani G; Cignetti A; Aglietta M; Sangiolo D. | |
| Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. | 2012 | Mesiano G; Todorovic M; Gammaitoni L; Leuci V; Giraudo Diego L; Carnevale-Schianca F; Fagioli F; Piacibello W; Aglietta M; Sangiolo D. | |
| Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways | 2012 | Pignochino, Y.; Dell'Aglio, C.; Basirico, M.; Capozzi, F.; Tarraran, L.; Soster, M.; Marchio, S.; Bruno, S.; Gammaitoni, L.; Sangiolo, D.; D'ambrosio, L.; Picci, P.; Aglietta, M.; Grignani, G. | |
| Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer | 2012 | M. Todorovic; S. Corso; L. Gammaitoni; V. Leuci; G. Mesiano; L. Giraudo Diego; S. Capellero; S. Giordano; M. Aglietta; D. Sangiolo | |
| Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? | 2011 | Carnevale-Schianca F; Gallo S; Rota-Scalabrini D; Sangiolo D; Fizzotti M; Caravelli D; Capaldi A; Anselmetti G; Palesandro E; D'Ambrosio L; Coha V; Obert R; Aglietta M; Grignani G. | |
| Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. | 2011 | Sangiolo D; Leuci V; Gallo S; Aglietta M; Piacibello W. | |
| Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. | 2011 | Leuci V; Mesiano G; Gammaitoni L; Cammarata C; Capellero S; Todorovic M; Jordaney N; Circosta P; Elia A; Lesnikova M; Georges GE; Piacibello W; Fagioli F; Cignetti A; Aglietta M; Sangiolo D | |
| Cytokine induced killer cells as promising immunotherapy for solid tumors | 2011 | Sangiolo, Dario | |
| Comparison of post-transplant events and outcomes in patients affected by haematological or solid malignancies undergone to a non-myeloablative allogeneic haematopoietic stem cell transplantation in progressive disease | 2010 | Caravelli D; Carnevale-Schianca F; Bruno B; Coha V; Sorasio R; Grignani G; Rota-Scalabrini D; Fizzotti M; Gatti M; Giaccone L; Capaldi A; Cignetti A; Sangiolo D; Boccadoro M; Aglietta M | |
| Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. | 2010 | Sangiolo D;Storb R;Deeg HJ;Flowers ME;Martin PJ;Sandmaier BM;Kiem HP;Nash RA;Doney K;Leisenring WM;Georges GE |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile